A mechanistic, functional, and clinical perspective on targeting CD70 in cancer

Cancer Letters, Journal Year: 2024, Volume and Issue: 611, P. 217428 - 217428

Published: Dec. 24, 2024

The oncoimmunology research has witnessed notable advancements in recent years. Reshaping the tumor microenvironment (TME) approach is an effective method to improve antitumor immune response. T cell-mediated response crucial for favorable therapeutic outcomes several cancers. United States Food and Drug Administration (FDA) approved checkpoint inhibitors (ICIs) targeting proteins (ICPs) expressed various hematological solid malignancies. ICPs are cell co-inhibitory molecules that block activation and, thus, Currently, most of FDA-approved ICIs antagonistic antibodies programmed death-ligand 1 (PD-L1), death protein (PD-1), cytotoxic T-lymphocyte-associated 4 (CTLA-4). In contrast ICPs, costimulatory required activation, expansion, effector function. However, abrupt expression these tumors presents a concern One molecules, cluster differentiation 70 (CD70), emerged as druggable target malignancies due its role function evasion. present review describes CD70, factors affecting CD70 expression, physiological clinical relevance current approaches

Language: Английский

---

Technology Spotlight Surface Target Discovery for Blood Cancer Immunotherapies

The Hematologist, Journal Year: 2025, Volume and Issue: 22(1)

Published: Jan. 1, 2025

Language: Английский

---

Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Aug. 5, 2024

Asthma poses a major public health burden. While existing asthma drugs manage symptoms for many, some patients remain resistant. The lack of cure, especially severe asthma, compels exploration novel therapies. Cancer immunotherapy successes with CAR-T cells suggest its potential treatment. Researchers are exploring various approaches allergic diseases including membrane-bound IgE, IL-5, PD-L2, and CTLA-4 Dectin-1 fungal asthma. NK offer several advantages over T CAR-based immunotherapy. They key benefits: (1) HLA compatibility, meaning they can be used in wider range without the need matching tissue types. (2) Minimal side effects (CRS GVHD) due to their limited persistence cytokine profile. (3) Scalability "off-the-shelf" production from sources. Several strategies have been introduced that highlight superiority challenges CAR-NK cell therapy treatment IL-10, IFN-γ, ADCC, perforin-granzyme, FASL, KIR, NCRs (NKP46), DAP, DNAM-1, TGF-β, TNF-α, CCL, NKG2A, TF, EGFR. Furthermore, we advocate incorporating AI CAR design optimization CRISPR-Cas9 gene editing technology precise manipulation generate highly effective constructs. This review will delve into evolution designs, explore pre-clinical clinical studies therapies analyze optimize function, conduct comparative analysis respective challenges, finally present established designs promising

Language: Английский

---

Cellular Therapies for Multiple Myeloma: Engineering Hope

Cancers, Journal Year: 2024, Volume and Issue: 16(22), P. 3867 - 3867

Published: Nov. 19, 2024

Multiple myeloma (MM) treatment remains challenging due to its relapsed/refractory disease course as well intra- and inter-patient heterogeneity. Cellular immunotherapies, especially chimeric antigen receptor (CAR)-T cells targeting B cell maturation (BCMA), mark a major breakthrough, achieving long-lasting remissions instilling hope for potential cure. While ongoing clinical trials are increasingly driving approved cellular products towards earlier lines of therapy, novel targets advanced approaches employing natural killer (NK) or dendritic (DC) vaccines currently under investigation. Treatment resistance, driven by tumor-intrinsic factors such escape the intricate dynamics tumor microenvironment (TME), along with emerging side effects movement neurocognitive treatment-emergent adverse events (MNTs), limitations therapies. To improve efficacy overcome cutting-edge research is exploring strategies target synergistic combinatorial approaches. Recent advances in CAR-T production involve shortened manufacturing protocols "off-the-shelf" cells, aiming at decreasing socioeconomic barriers thereby increasing patient access this lifesaving therapy. In review, we provide an extensive overview evolving field therapies MM, underlining achieve responses.

Language: Английский

---